Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05975073 · ClinicalTrials.gov registry record · Phase 1
A Phase 1/2 Study of AMG 193 in Combination With IDE397 in Participants With Advanced Methylthioadenosine Phosphorylase (MTAP)-Null Solid Tumors
A Phase 1 study of MTAP-null Non-Small-Cell Lung Cancer and MTAP-null Solid Tumors, sponsored by Amgen.
- Active
- Registry status
- Phase 1
- Development phase
- 53
- Enrollment target
- 20
- Study locations
NCT05975073: Active Phase 1 study of MTAP-null Non-Small-Cell Lung Cancer and MTAP-null Solid Tumors, sponsored by Amgen.
NCT05975073 is a Phase 1 study of MTAP-null Non-Small-Cell Lung Cancer and MTAP-null Solid Tumors that is active but no longer recruiting, run by Amgen. The registered enrollment target is 53 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (12% lower). The trial reports 20 study locations across 16 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05975073, a Phase 1 study of MTAP-null Non-Small-Cell Lung Cancer and MTAP-null Solid Tumors, is active but no longer recruiting, sponsored by Amgen.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 53 participants
- Enrollment target
- 20
- Study locations
Study Summary
The main aims of this study are to evaluate the safety and tolerability, and to determine the maximum tolerated dose (MTD) or the recommended combination dose of AMG 193 in combination with IDE397 in adult participants with metastatic or locally advanced MTAP-null solid tumors, and to evaluate the preliminary anti-tumor activity of AMG 193 in combination with IDE397 in adult participants with metastatic or locally advanced MTAP-null Non-Small-Cell Lung Cancer (NSCLC).
Conditions Studied
Interventions
- DRUG AMG 193
- DRUG IDE397
Study Locations (20)
New York
- New York University Grossman School of Medicine and New York University Langone Hospitals - New York
- Columbia University Irving Medical Center - New York
- Memorial Sloan Kettering Cancer Center - New York
Texas
- University of Texas MD Anderson Cancer Center - Houston
- Next Oncology - Irving
Other
- Rigshospitalet - Copenhagen
- Seoul National University Bundang Hospital - Seongnam-si, Gyeonggi-do
California
- City of Hope National Medical Center - Duarte
Colorado
- Sarah Cannon Research Institute - Denver
Indiana
- Community Health Network MD Anderson Cancer Center - North - Indianapolis
Massachusetts
- Dana Farber Cancer Institute - Boston
Michigan
- University of Michigan - Ann Arbor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 53 participants |
| Start Date | 2023-08-01 |
| Est. Completion | 2026-04-01 |
| Phase | Phase 1 |
What the registry record for NCT05975073 still lists
NCT05975073 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 53 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (12% lower).
The record links to 2 conditions, with MTAP-null Non-Small-Cell Lung Cancer appearing as the primary indexed condition, and to 2 interventions - of which AMG 193 is the first listed.
NCT05975073 names 20 study sites across 16 states, led by New York, Texas, Other.
Frequently Asked Questions
What is clinical trial NCT05975073 about?
NCT05975073 is a clinical study titled "A Phase 1/2 Study of AMG 193 in Combination With IDE397 in Participants With Advanced Methylthioadenosine Phosphorylase (MTAP)-Null Solid Tumors". The main aims of this study are to evaluate the safety and tolerability, and to determine the maximum tolerated dose (MTD) or the recommended combination dose of AMG 193 in combination with IDE397 in adult participants with metastatic or locally advanced MTAP-null solid tumors, and to evaluate the p...
What is the current status of trial NCT05975073?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 53 participants. The study started on 2023-08-01. Estimated completion is 2026-04-01.
What conditions does trial NCT05975073 study?
This clinical trial studies the following conditions: MTAP-null Non-Small-Cell Lung Cancer, MTAP-null Solid Tumors.
What interventions are being tested in trial NCT05975073?
The interventions under investigation include: AMG 193 (DRUG), IDE397 (DRUG).
Who is sponsoring clinical trial NCT05975073?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05975073 being conducted?
This trial has 20 study locations across California, Colorado, Indiana, Massachusetts, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05975073's enrollment target sits among peer trials
53 948th of 2000 higher than 1,045 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04177004 · 53 participants · Phase 1
Human Lysozyme Goat Milk for the Prevention of Graft Versus Host Disease in Patients With Blood Cancer Undergoing a Donor Stem Cell Transplant
- NCT04199741 · 53 participants · Phase 1
PET/CT Imaging of Small Cell Lung Cancer Using 89Zr-DFO-SC16.56
- NCT04835129 · 53 participants · Phase 2
Isatuximab, Pomalidomide, Elotuzumab and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma
- NCT04913805 · 53 participants · Phase 2
Matching Perfusion and Metabolic Activity in HFpEF
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI